Press Release

January 17th 2018

Appriss Health Signs an Agreement with Delaware to Deliver NarxCare to All Prescribers and Pharmacists Statewide

Industry-Leading Substance Use Disorder Platform Now Available to All Prescribers and Pharmacists in Delaware to Help Identify, Manage and Prevent Prescription Drug Misuse, Abuse and Diversion

LOUISVILLE, KY – January 17, 2018 – Appriss Health, provider of the most comprehensive platform for substance use disorder in the U.S., today announced that it has signed an enterprise license agreement with the Delaware Division of Professional Regulation to make NarxCare, an advanced analytics and patient support solution, available to all eligible prescribers and pharmacists in Delaware. Through this state-sponsored program, access is provided to NarxCare through the web portal for DELAware PMP, the state’s prescription drug monitoring program (PDMP).

NarxCare is a comprehensive platform that aggregates and analyzes prescription information from providers and pharmacies and presents visual, interactive information, as well as advanced analytic insights, complex risk scores and more to help physicians, pharmacists and care teams to provide better patient safety and outcomes. NarxCare also provides tools and resources that support patients’ needs and connects them to treatment.

“The purpose of our prescription drug monitoring program is to reduce the misuse of controlled substances in Delaware and to promote improved professional practice and patient care,” said David Mangler, Director, Delaware Division of Professional Regulation. “Partnering with Appriss Health to deliver NarxCare bolsters our prescription drug monitoring program’s overall effectiveness and benefits all of our state’s prescribers, pharmacists, and patients. Together, we can help address this most serious threat to the health and safety of all of the citizens of Delaware.”

This NarxCare enterprise license agreement enables Delaware to deliver access to all of the features and functions of NarxCare in a consistent look and feel for users who access the solution through their state PDMP web portal. It also enables delivery of NarxCare within EHRs and pharmacy management systems for those prescribers and dispensers in Delaware that choose to access NarxCare through integration within their healthcare IT system via Appriss Health’s PMP Gateway solution.

“This agreement with Delaware marks a significant milestone in the evolution and growth of PDMPs nationwide,” said Rob Cohen, President, Appriss Health. “The NarxCare substance use disorder platform supports state PDMPs and their efforts to maximize the effectiveness of their programs. Moreover, with the pairing of PDMPs and the NarxCare platform, clinicians can interact with, and treat their patients more effectively.”

For more information, please visit https://dpr.delaware.gov/boards/pmp/.

About Appriss Health

Appriss Health provides the nation’s most comprehensive platform for early identification, prevention and management of substance use disorder (SUD). We provide state government agencies with the most advanced repository of controlled substance dispensing data, and deliver real-time clinical decision supports, critical insights and interventions to physicians, pharmacists, and care team members through millions of patient encounters each year. Our solutions enable healthcare providers, pharmacists, and care team members to assess and manage clinical risk in order to positively impact patient safety and population health outcomes. For more information, please visit www.apprisshealth.com.

CONTACT INFORMATION

David Griffin
Vice President of Marketing
Appriss Health
dgriffin@apprisshealth.com
502-815-3880